Loading
NASDAQHealthcareBiotechnology
Latest quote
$45.305
+$2.005 · +4.63%
Founded in 1989 and headquartered in Carlsbad, California, Ionis Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapies within the United States. Its commercial portfolio includes three key medications: SPINRAZA, prescribed for spinal muscular atrophy (SMA) in both children and adults; TEGSEDI, an injectable treatment targeting polyneuropathy associated with hereditary transthyretin-mediated amyloidosis in adult patients; and WAYLIVRA, which addresses familial chylomicronemia syndrome and familial partial lipodystrophy. Ionis also maintains a robust pipeline, with several drug candidates currently in Phase 3 clinical trials. These include Eplontersen, a monthly self-administered subcutaneous injection designed for all forms of TTR amyloidosis; Olezarsen, intended for individuals with severe hypertriglyceridemia (SHTG); Donidalorsen, for patients suffering from hereditary angioedema; ION363, aimed at amyotrophic lateral sclerosis (ALS); Pelacarsen, developed for those with established cardiovascular disease and elevated lipoprotein(a); and Tofersen, which works by inhibiting the production of superoxide dismutase 1. Beyond these late-stage assets, the company is actively researching treatments for metabolic, infectious, renal, and ophthalmic diseases, as well as various types of cancer. The firm engages in significant collaborations, notably a strategic partnership with Biogen Inc. Additionally, it holds licensing and collaboration agreements with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc.
Regular session
$45.305
+$2.005 · +4.63%
Regular session · ET · Market data may be delayed.
Founded in 1989 and headquartered in Carlsbad, California, Ionis Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapies within the United States. Its commercial portfolio includes three key medications: SPINRAZA, prescribed for spinal muscular atrophy (SMA) in both children and adults; TEGSEDI, an injectable treatment targeting polyneuropathy associated with hereditary transthyretin-mediated amyloidosis in adult patients; and WAYLIVRA, which addresses familial chylomicronemia syndrome and familial partial lipodystrophy. Ionis also maintains a robust pipeline, with several drug candidates currently in Phase 3 clinical trials. These include Eplontersen, a monthly self-administered subcutaneous injection designed for all forms of TTR amyloidosis; Olezarsen, intended for individuals with severe hypertriglyceridemia (SHTG); Donidalorsen, for patients suffering from hereditary angioedema; ION363, aimed at amyotrophic lateral sclerosis (ALS); Pelacarsen, developed for those with established cardiovascular disease and elevated lipoprotein(a); and Tofersen, which works by inhibiting the production of superoxide dismutase 1. Beyond these late-stage assets, the company is actively researching treatments for metabolic, infectious, renal, and ophthalmic diseases, as well as various types of cancer. The firm engages in significant collaborations, notably a strategic partnership with Biogen Inc. Additionally, it holds licensing and collaboration agreements with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc.
Day range
Current $45.305
52-week range
Current $45.305
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
77
Undervalued
Sentiment
67
Bullish
Risk
49
Elevated Risk
Momentum
31
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Founded in 1989 and headquartered in Carlsbad, California, Ionis Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapies within the United States. Its commercial portfolio includes three key medications: SPINRAZA, prescribed for spinal muscular atrophy (SMA) in both children and adults; TEGSEDI, an injectable treatment targeting polyneuropathy associated with hereditary transthyretin-mediated amyloidosis in adult patients; and WAYLIVRA, which addresses familial chylomicronemia syndrome and familial partial lipodystrophy. Ionis also maintains a robust pipeline, with several drug candidates currently in Phase 3 clinical trials. These include Eplontersen, a monthly self-administered subcutaneous injection designed for all forms of TTR amyloidosis; Olezarsen, intended for individuals with severe hypertriglyceridemia (SHTG); Donidalorsen, for patients suffering from hereditary angioedema; ION363, aimed at amyotrophic lateral sclerosis (ALS); Pelacarsen, developed for those with established cardiovascular disease and elevated lipoprotein(a); and Tofersen, which works by inhibiting the production of superoxide dismutase 1. Beyond these late-stage assets, the company is actively researching treatments for metabolic, infectious, renal, and ophthalmic diseases, as well as various types of cancer. The firm engages in significant collaborations, notably a strategic partnership with Biogen Inc. Additionally, it holds licensing and collaboration agreements with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc.
Day range
Current $45.305
52-week range
Current $45.305
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$84.08
85.59% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI301.79M0.01%2.3T USD0.03%$381.74+0.57%
Vanguard Morningstar Small-Cap ETFVB218.08M0.12%185.3B USD0.03%$289.33+0.59%
Vanguard Morningstar Small-Cap Growth ETFVBK125.17M0.27%44.7B USD0.05%$344.5+1.15%
State Street SPDR S&P Biotech ETFXBI118.49M1.17%10.11B USD0.35%$154.27+3.34%
Vanguard Extended Market ETFVXF115.94M0.12%95.4B USD0.05%$234.8+0.72%
Capital Group Growth ETFCGGR59.58M0.22%26.39B USD0.39%$48.385+1.10%
iShares Biotechnology ETFIBB54.68M0.52%10.41B USD0.44%$206.5+3.00%
Schwab U.S. Small-Cap ETFSCHA38.83M0.18%21.73B USD0.03%$32.795+0.41%Vanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Growth ETFVBKState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFCapital Group Growth ETFCGGRiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
